Zai Lab Limited (NASDAQ:ZLAB - Get Free Report) CFO Yajing Chen sold 924 shares of the stock in a transaction on Friday, April 4th. The stock was sold at an average price of $33.11, for a total value of $30,593.64. Following the transaction, the chief financial officer now directly owns 27,047 shares in the company, valued at $895,526.17. The trade was a 3.30 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Yajing Chen also recently made the following trade(s):
- On Wednesday, April 2nd, Yajing Chen sold 5,280 shares of Zai Lab stock. The stock was sold at an average price of $35.89, for a total transaction of $189,499.20.
Zai Lab Trading Down 6.0 %
Shares of ZLAB opened at $27.07 on Wednesday. The firm has a market cap of $2.97 billion, a PE ratio of -9.77 and a beta of 1.09. Zai Lab Limited has a 12 month low of $13.48 and a 12 month high of $39.77. The stock has a fifty day moving average price of $32.76 and a 200-day moving average price of $28.96.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.19). Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. The business had revenue of $109.07 million during the quarter, compared to analyst estimates of $110.15 million. As a group, research analysts forecast that Zai Lab Limited will post -2.58 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on ZLAB shares. Bank of America reiterated a "neutral" rating and set a $36.10 price objective (up from $29.00) on shares of Zai Lab in a research note on Monday, March 3rd. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zai Lab in a report on Thursday, March 27th. JPMorgan Chase & Co. boosted their price target on Zai Lab from $44.00 to $51.00 and gave the stock an "overweight" rating in a research report on Thursday, March 13th. Finally, Scotiabank began coverage on Zai Lab in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $55.00 target price on the stock.
Read Our Latest Research Report on ZLAB
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the stock. Principal Financial Group Inc. acquired a new position in shares of Zai Lab in the 4th quarter valued at $46,172,000. Raymond James Financial Inc. purchased a new stake in Zai Lab during the 4th quarter valued at about $1,032,000. Alberta Investment Management Corp increased its holdings in shares of Zai Lab by 42.9% in the fourth quarter. Alberta Investment Management Corp now owns 232,293 shares of the company's stock valued at $6,084,000 after purchasing an additional 69,740 shares during the period. Geode Capital Management LLC raised its stake in shares of Zai Lab by 26.4% in the third quarter. Geode Capital Management LLC now owns 43,626 shares of the company's stock worth $1,053,000 after purchasing an additional 9,107 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Zai Lab by 28.9% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 183,317 shares of the company's stock worth $4,801,000 after purchasing an additional 41,128 shares during the period. Institutional investors and hedge funds own 41.65% of the company's stock.
Zai Lab Company Profile
(
Get Free Report)
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
